New synthetic ligands for L-type voltage-gated calcium channels.
The pharmacology of the L-type Ca2+ channel has been the subject of considerable basic and clinical investigation over the past two decades primarily because of the clinical activities of nifedipine, verapamil and diltiazem. However, it is quite clear that this Ca2+ channel is, in common with other pharmacologic receptors, a multiple drug receptor. There are probably as many as six or more discrete drug binding sites associated with this Ca2+ channel. Continued investigation of these sites may yield both new therapeutic agents, structural clues to ligands active at other classes of Ca2+ channel and structures active at other classes of ion channel.
Marion Merrell Dow Research Institute, Cincinnati, Ohio 45215.
D
D
Rampe
D J
DJ
Triggle
D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D015220:Calcium Channels / Q000187:drug effects*; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects*
D002121:Calcium Channel Blockers; D015220:Calcium Channels